Bangor Savings Bank Has $470,000 Holdings in Bristol-Myers Squibb Company (BMY)

Bangor Savings Bank raised its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 71.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,423 shares of the biopharmaceutical company’s stock after buying an additional 3,513 shares during the period. Bangor Savings Bank’s holdings in Bristol-Myers Squibb were worth $470,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Renaissance Technologies LLC boosted its position in shares of Bristol-Myers Squibb by 108.5% during the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after purchasing an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock valued at $339,830,000 after purchasing an additional 3,960,191 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Bristol-Myers Squibb by 2,990.5% during the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock valued at $202,494,000 after purchasing an additional 3,516,536 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Bristol-Myers Squibb by 42,071.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock valued at $185,634,000 after purchasing an additional 3,323,649 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after purchasing an additional 2,451,390 shares in the last quarter. Hedge funds and other institutional investors own 69.82% of the company’s stock.

BMY has been the topic of several research analyst reports. Credit Suisse Group restated a “hold” rating and set a $61.00 target price (up previously from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Cowen restated a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Jefferies Group upped their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Leerink Swann upped their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $64.93.

In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $63.47 on Thursday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market capitalization of $103,570.38, a P/E ratio of 21.38, a P/E/G ratio of 2.40 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company posted $0.77 earnings per share. analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.

ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/14/bangor-savings-bank-has-470000-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply